《亚砷酸联合甘露醇对急性早幼粒细胞白血病中枢神经系统复发浸润的治疗》解读

王宏; 兰文家; 周晋

doi:10.13201/j.issn.1004-2806.2015.03.001

《亚砷酸联合甘露醇对急性早幼粒细胞白血病中枢神经系统复发浸润的治疗》解读

- 哈尔滨医科大学附属第一医院血液科黑龙江省血液肿瘤研究所(哈尔滨, 150001)

详细信息

通讯作者: 周晋,E-mail:zhoujin1111@126.com

中图分类号: R733

收稿日期: 2015-01-13

Comments on “Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system”

More Information

Corresponding author: ZHOU Jin, E-mail: zhoujin1111@126.com

Received Date: 13 January 2015

摘要

- 白血病,早幼粒细胞,急性 /
- 中枢神经系统 /
- 亚砷酸 /
- 甘露醇
- acute promyelocytic leukemia /
- central nervous system /
- arsenic trioxide /
- mannitol

HTML全文

参考文献(34)

[1]	Bennett JM,Catovsky D,Daniel MT,et al.Proposals for the classification of the acute leukaemias.French-American-British (FAB) co-operative group[J].Br J Haematol,1976,33:451-458.
[2]	Rowley JD.Identification of the constant chromosome regions involved in human hematologic malignant disease[J].Science,1982,216:749-751.
[3]	de Thé H,Chomienne C,Lanotte M,et al.The t (15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus[J].Nature,1990,347:558-561.
[4]	Chen SJ,Zelent A,Tong JH,et al.Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t (11;17)(q23;q21) in a patient with acute promyelocytic leukemia[J].J Clin Invest,1993,91:2260-2267.
[5]	Redner RL,Rush EA,Faas S,et al.The t (5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion[J].Blood,1996,87:882-886.
[6]	Wells RA,Catzavelos C,Kamel-Reid S.Fusion of retinoic acid receptor alpha to NuMA,the nuclear mitotic apparatus protein,by a variant translocation in acute promyelocytic leukaemia[J].Nat Genet,1997,17:109-113.
[7]	Zhang XW,Yan XJ,Zhou ZR,et al.Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML[J].Science,2010,328:240-243.
[8]	Jeanne M,Lallemand-Breitenbach V,Ferhi O,et al.PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3[J].Cancer Cell,2010,18:88-98.
[9]	Zhu J,Gianni M,Kopf E,et al.Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins[J].Proc Natl Acad Sci U S A,1999,96:14807-14812.
[10]	Zhu J,Koken MH,Quignon F,et al.Arsenic-induced PML targeting onto nuclear bodies:implications for the treatment of acute promyelocytic leukemia[J].Proc Natl Acad Sci U S A,1997,94:3978-3983.
[11]	Chen GQ,Shen ZX,Wu F,et al.Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia[J].Leukemia,1996,10:825-828.
[12]	Mi JQ,Li JM,Shen ZX,et al.How to manage acute promyelocytic leukemia[J].Leukemia,2012,26:1743-1751.
[13]	Park JH,Tallman MS.Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy[J].Oncology (Williston Park),2011,25:733-741.
[14]	Adès L,Guerci A,Raffoux E,et al.Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy:the European APL Group experience[J].Blood,2010,115:1690-1696.
[15]	Sahin DG,Gunduz E,Akay OM,et al.Central nervous system relapse in a patient with acute promyelocytic leukaemia:does the risk stratification matter?[J].BMJ Case Rep,2013,doi:10.1136/bcr-2013-009456.
[16]	Huang H,Qin Y,Xu R,et al.Combination therapy with arsenic trioxide,all-trans retinoic acid,and chemotherapy in acute promyelocytic leukemia patients with various relapse risks[J].Leuk Res,2012,36:841-845.
[17]	Housman E,Chang P,Lane SW,et al.CNS relapse in acute promyeloctyic leukemia[J].J Clin Oncol,2010,28:e409-e411.
[18]	Kim SH,Yun J,Kim HJ,et al.Long-term survival in a patient with acute promyelocytic leukemia with isolated meningeal relapse[J].Korean J Hematol,2010,45:208-210.
[19]	Sanz MA,Grimwade D,Tallman MS,et al.Management of acute promyelocytic leukemia:recommendations from an expert panel on behalf of the European LeukemiaNet[J].Blood,2009,113:1875-1891.
[20]	Jabbour E,Thomas D,Cortes J,et al.Central nervous system prophylaxis in adults with acute lymphoblastic leukemia:current and emerging therapies[J].Cancer,2010,116:2290-2300.
[21]	Nagai S,Takahashi T,Kurokawa M.The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia[J].Curr Stem Cell Res Ther,2010,5:372-378.
[22]	Zhou J,Zhang Y,Li J,et al.Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia[J].Blood,2010,115:1697-1702.
[23]	张鹏,王树叶,胡龙虎,等.三氧化二砷治疗急性早幼粒细胞白血病七年总结-附242例分析[J].中华血液学杂志,2000,21(2):67-70.
[24]	Au WY,Tam S,Fong BM,et al.Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy[J].Blood,2008,112:3587-3590.
[25]	孟然,周晋,王德胜.甘露醇暂时渗透性开放血脑屏障的研究[J].中风与神经疾病杂志,2003,20(4):350-352.
[26]	周晋,孟然,王艳,等.三氧化二砷不同给药方法治疗急性粒细胞白血病的临床观察和随访[J].中华医学杂志,2004,84(5):405-408.
[27]	Jin Z,Ran M,Man Z.Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia[J].Haematologica,2007,92:e82-e84.
[28]	周晋,孟然,关秀茹,等.细胞内砷浓度与三氧化二砷治疗敏感性的关系[J].中国药学杂志,2004,39(3):193-195.
[29]	Zhou J,Meng R,Sui X,et al.Various tolerances to arsenic trioxide between human cortical neurons and leukemic cells[J].Sci China C Life Sci,2006,49:567-572.
[30]	周晋,孟然,宋学明,等.恶性肿瘤与神经元胞内三氧化二砷浓度与敏感性[J].中华医学杂志,2004,84(1):63-64.
[31]	周晋,孟然,李丽敏,等.神经节苷脂对染砷人脑皮层神经元的保护作用[J].中国药学杂志,2006,41(1):29-33.
[32]	Testi AM,Biondi A,Lo Coco F,et al.GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children[J].Blood,2005,106:447-453.
[33]	Soignet SL,Frankel SR,Douer D,et al.United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia[J].J Clin Oncol,2001,19:3852-3860.
[34]	Guha Mazumder DN.Chronic arsenic toxicity & human health[J].Indian J Med Res,2008,128:436-447.